BioAsia 2026 Sets New Benchmark, Strengthens Telangana’s Global TechBio Leadership

HYDERABAD: The 23rd edition of BioAsia 2026 concluded in Hyderabad with record-breaking participation, drawing over 4,500 delegates and facilitating more than 4,000 high-impact B2B meetings. The event reinforced Telangana’s position as a global life sciences and TechBio hub, spotlighting

innovation, strategic partnerships, and investment opportunities aligned with the state’s long-term economic vision.

The three-day forum witnessed participation from global delegates, policymakers, industry leaders, startups, and researchers exploring advancements in AI-driven healthcare, biotechnology, and advanced therapeutics. The closing ceremony followed a fireside chat with Sri D. Sridhar Babu, Hon’ble Minister for Industries and Commerce, Government of Telangana, who outlined the roadmap under the Rising Telangana Vision 2047, targeting a $3 trillion economy.

Addressing the audience, Sri D. Sridhar Babu said, “BioAsia 2026 has been a phenomenal success and once again demonstrated Telangana’s strong leadership in the global life sciences and TechBio ecosystem. This year’s theme, ‘TechBio Unleashed: AI, Automation, and the Biology Revolution,’ perfectly captures the transformative potential of merging biology with cutting-edge technologies. Telangana is committed to building a future-ready ecosystem that translates scientific breakthroughs into practical healthcare solutions. By far, this has been the most successful edition of Bio Asia to date, creating pathways to global partnerships, fostering innovation in AI, automation, cell and gene therapies, and advanced manufacturing. The state has seen significant international engagement this year, with global companies from France, Indonesia, the USA and Novartis celebrating Hyderabad as a key hub for investment and innovation. Initiatives like the Next Gen Life Sciences Policy 2026–30 are designed to ensure that Telangana continues to attract global capital, talent, and expertise while delivering solutions that improve patient outcomes worldwide. This establishes BioAsia as a true landmark event in the life sciences every calendar year.”

According to Sri Sanjay Kumar (IAS), Special Chief Secretary, Industries and Commerce, Government of Telangana, “BioAsia 2026 reflects Telangana’s vision to catalyse industry growth through innovation and cross-border collaboration. This platform enables startups, researchers, and industry leaders to come together to explore next-generation technologies and solutions in healthcare. The state’s focus on advanced therapeutics, digital health, precision medicine, AI-driven drug discovery, and CRDMO innovations ensures a robust ecosystem that is future-ready and globally competitive. By combining policy foresight with strong infrastructure and regulatory support, Telangana is fostering a collaborative environment that will continue to drive transformative impact in the life sciences sector.”

In his concluding remarks, Mr. Shakti M Nagappan, CEO, Telangana Life Sciences, added, “This edition of Bio Asia 2026 was the most successful edition of the marquee Life Sciences Seminar, recording the highest number of delegates and discussions. The partnerships forged and avenues created at Bio Asia 2026 will act as a catalyst to drive the next phase of Innovation Led Growth in Telangana’s Life Sciences journey.”

The valedictory ceremony was attended by senior officials including Sri Sanjay Kumar IAS, Sri B P Acharya IAS (Retd), and Dr Jitendra Kumar, MD, BIRAC, Government of India, alongside other industry and government dignitaries. The event featured distinguished speakers such as Prof. Bruce L. Levine (University of Pennsylvania), Dr. Howard Y. Chang (Amgen, USA), Pushmeet Kohli (Google DeepMind, UK), and Ms. Madeleine Roach (Sanofi, France), who shared insights on AI-driven biomedical discovery, next-generation biologics, CRDMO innovation, and resilient healthcare systems.

Over 120 startups were shortlisted by an eminent jury, with more than 40 innovative ventures showcasing disruptive solutions across MedTech, BioPharma, Cell and Gene Therapy, AI, ML, Nutraceuticals, and Biomarkers. The BioAsia 2026 Innovation Awards were conferred on Achala Health Services Private Limited, Exquinz Life Sciences Pvt Ltd, Helex, Natural Solutions & Nutraceuticals Pvt Ltd, and Sree Guravey Life Sciences OPC Pvt Ltd.

The final day featured four panel discussions covering innovation-first Global Capability Centres (GCCs), patient-centric transformation, India’s shift toward innovation-led leadership, and financing TechBio and deep-tech manufacturing. Discussions emphasized the role of GCCs in driving digital transformation, advanced R&D, and measurable patient impact while addressing funding requirements for sustaining innovation ecosystems.

As the curtains closed, the forum reaffirmed its role as a bridge between innovation and enterprise. With strengthened international participation, landmark collaborations, and rising investor confidence, momentum is already building for the next edition, promising further advancement in life sciences and TechBio leadership.

About BioAsia 2026:
BioAsia 2026 is the 23rd edition of Asia’s premier life sciences and health-tech forum, hosted in Hyderabad. The platform brings together global leaders, startups, policymakers, researchers, and investors to foster collaboration, innovation, and strategic partnerships across biotechnology, digital health, advanced therapeutics, and manufacturing. The 2026 edition recorded its highest-ever participation and B2B engagements, reinforcing Telangana’s standing as a global life sciences hub.
#BioAsia2026 #Telangana #LifeSciences #TechBio